JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Blood

• Publication date

  2007-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2007-07-099184PMID 17712047
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validation and comparison of contemporary prognostic models in primary myelofibrosis

  2007cited by this paper
• Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

  2007cited by this paper
• Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

  2007cited by this paper
• V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

  2006cited by this paper
• Oncogenes and Tumor Suppressors (795 articles)

  2006influential reference
• Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F

  2006influential reference
• Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

  2006cited by this paper
• JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

  2006influential reference
• Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

  2006cited by this paper
• The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera

  2006cited by this paper
• JAK2 V617F mutation in leukaemic transformation of philadelphia‐negative chronic myeloproliferative disorders

  2006cited by this paper
• JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.

  2006cited by this paper
• Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

  2006cited by this paper
• A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.

  2006cited by this paper
• JAK2V617F and leukemic transformation in myelofibrosis with myeloid metaplasia

  2006cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005influential reference
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005influential reference
• The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

  2005influential reference
• Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia

  2005influential reference
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  2005influential reference
• X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.

  2005cited by this paper
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005influential reference
• Idiopathic myelofibrosis.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

  2005influential reference
• Clinical implications of the JAK2 V617F mutation in essential thrombocythemia

  2005cited by this paper
• The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

  2005cited by this paper
• JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.

  2005cited by this paper
• The World Health Organization (WHO) classification of the myeloid neoplasms.

  2002cited by this paper
• Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera.

  2002influential reference
• Primary Chronic Myelofibrosis: Clinical and Prognostic Evaluation in 336 Japanese Patients

  2001influential reference
• Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.

  2001cited by this paper
• The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia

  1999cited by this paper
• Multiple imputation of missing blood pressure covariates in survival analysis.

  1999cited by this paper
• Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosis

  1997influential reference
• Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases

  1997influential reference
• Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

  1996cited by this paper
• Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients

  1990cited by this paper
• PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA

  1989cited by this paper
• A prognostic classification of myelofibrosis with myeloid metaplasia

  1988cited by this paper
• Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

  1985cited by this paper
• Idiopathic myelofibrosis.

  1984cited by this paper

• The Janus kinase 2 (JAK2) Mutation Burden is Related to Hematological Outcomes in Thai Patients with Myeloproliferative Neoplasms

  2025cites this paper
• Insight concerning the MPN driver mutations prevalence in Iraqi myelofibrosis patients

  2025cites this paper
• Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms

  2025cites this paper
• Frequency of JAK2V617F Mutation Zygosity and Impact on Disease Outcome in MPN Patients

  2025cites this paper
• JAK/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders

  2025cites this paper
• Clonal hematopoiesis and myeloid skewing in older population‐based individuals

  2024cites this paper
• Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

  2024cites this paper
• JAK/STAT in leukemia: a clinical update

  2024cites this paper
• Differences between aquagenic and non‐aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients

  2023cites this paper
• Contribution of lowered hemoglobin threshold value in the diagnosis of polycythemia vera: Comparison of 2016 and 2008 WHO criteria

  2023cites this paper
• Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments

  2023cites this paper
• Evolution of Janus Kinase 2 V617F-negative idiopathic myelofibrosis into Philadelphia+ chronic myeloid leukemia

  2023cites this paper
• Palpable spleen size is differently prognostic in primary and secondary myelofibrosis

  2023cites this paper
• Clonal evolution analysis of a rare acute promyelocytic leukemia patient transforming from essential thrombocythemia

  2023cites this paper
• Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms

  2023cites this paper
• JAK2V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes

  2023cites this paper
• Lectin-based carbohydrate profile of megakaryocytes in murine fetal liver during development

  2023cites this paper
• Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer

  2022cites this paper
• Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis

  2022cites this paper
• Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto‐oncogene, receptor tyrosine kinase (KIT) D816V mutations

  2021cites this paper
• The mortality outcomes and survival pattern of patients of Myeloproliferative Neoplasms in Malaysia

  2021cites this paper
• The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms

  2021cites this paper
• The gut microbiome contributes to splenomegaly and tissue inflammation in a murine model of primary biliary cholangitis

  2021cites this paper
• Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP

  2021cites this paper
• Mortality outcomes and survival patterns of patients with myeloproliferative neoplasms in Malaysia

  2021cites this paper
• Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants

  2021cites this paper
• Gujarat Cancer Society Research Journal

  2020cites this paper
• Prognostic models in the myeloproliferative neoplasms.

  2020cites this paper
• The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.

  2020cites this paper
• Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.

  2020cites this paper
• Modern management of splenomegaly in patients with myelofibrosis

  2020cites this paper
• Evaluation of the Effect of NQO1 C609T (rs1800566) Gene Variations in Philadelphia-negative Myeloproliferative Neoplasms in Turkish Population

  2020cites this paper
• Finding relationships among biological entities

  2020cites this paper
• Incidence in Ph-Negative Myeloproliferative Neoplasms in Armenia from 2005 to 2019

  2020cites this paper
• Myeloid, mast cell, histiocytic and dendritic cell neoplasms and proliferations involving the spleen.

  2020cites this paper
• Allogeneic hematopoietic stem-cell transplantation for myelofibrosis

  2020cites this paper
• Shaking Up the Genome

  2019cites this paper
• Trapped by Evolution

  2019cites this paper
• The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.

  2019cites this paper
• Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India

  2019cites this paper
• Mutation Status in Myeloid Malignancies Informs Clinical Insight

  2019cites this paper
• Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance

  2018cites this paper
• Retrospective analysis of patients with chronic myeloproliferative neoplasms: a single center experience

  2018cites this paper
• Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms

  2018cites this paper
• Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.

  2018cites this paper
• Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis

  2018cites this paper
• JAK2, MPL, and CALR Testing for Myeloproliferative Neoplasms

  2018cites this paper
• Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms

  2018cites this paper
• JAK2, MPL, and CALR Testing for Myeloproliferative Neoplasms

  2018cites this paper
• Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta‐analysis

  2018cites this paper
• Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls

  2018cites this paper
• Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia

  2018cites this paper
• The Precision of the Rare Diseases

  2018cites this paper
• Genetics: Clues, Not Answers, to the Mysteries of Precision Medicine

  2018cites this paper
• Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.

  2018cites this paper
• Genetic Testing for Myeloid Neoplasms and Leukemia Effective : October 1 , 2017

  2017cites this paper
• Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey

  2017cites this paper
• Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories

  2017cites this paper
• An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

  2017cites this paper
• MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction

  2017cites this paper
• Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature

  2017cites this paper
• Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms

  2017cites this paper
• Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies

  2017cites this paper
• A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

  2017cites this paper
• JAK 2 , MPL , and CALR Testing for Myeloproliferative Neoplasms Policy # 00420

  2017cites this paper
• Acute megakaryoblastic transformation from essential thrombocythemia

  2017cites this paper
• The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis

  2017cites this paper
• Genetic Testing for Myeloid Neoplasms and Leukemia Effective : September 1 , 2017

  2017cites this paper
• Genetic Testing for Myeloid Neoplasms and Leukemia Effective : August 1 , 2017

  2017cites this paper
• A portable microfluidic platform for rapid molecular diagnostic testing of patients with myeloproliferative neoplasms

  2017cites this paper
• Pronostic et prise en charge des grossesses chez les patientes porteuses d’une néoplasie myeloproliférative philadelphia-négative

  2017influential citation
• Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden

  2017cites this paper
• Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches

  2016cites this paper
• Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors

  2016cites this paper
• Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?

  2016cites this paper
• Myeloproliferative neoplasms: Current molecular biology and genetics.

  2016cites this paper
• Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience

  2016cites this paper
• Acquired uniparental disomy of chromosome 9p in hematologic malignancies.

  2016cites this paper
• Molecular biomarkers of thrombosis in myeloproliferative neoplasms.

  2016cites this paper
• Prognosis of Primary Myelofibrosis in the Genomic Era.

  2016cites this paper
• The evolution and clinical relevance of prognostic classification systems in myelofibrosis

  2016cites this paper
• Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis

  2016cites this paper
• Brief report Characteristics and clinical correlates of MPL 515WL/K mutation in essential thrombocythemia

  2016cites this paper
• Interferon‐α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F‐positive essential thrombocythemia and polycythemia vera

  2016cites this paper
• Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)

  2016cites this paper
• Biology of Myeloproliferative Malignancies

  2016cites this paper
• Pruritus in Hematological Diseases (Including Aquagenic Pruritus)

  2016cites this paper
• Three general concepts to improve risk prediction: good data, wisdom of the crowd, recalibration

  2016cites this paper
• BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.

  2015influential citation
• Prognostication in myelofibrosis

  2015cites this paper
• JAK-2 V617F Mutational Analysis in Primary Idiopathic Myelofibrosis: Experience from Southern Pakistan.

  2015cites this paper
• The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.

  2015cites this paper
• Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations.

  2015cites this paper
• A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms

  2015cites this paper
• Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression

  2015cites this paper
• Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.

  2015cites this paper
• What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

  2015cites this paper
• Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis

  2015cites this paper
• JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients

  2015cites this paper
• [Urticarial vasculitis associated with essential thrombocythaemia progressing to myelofibrosis].

  2014cites this paper